OLMA News and Press, Olema Pharmaceuticals Inc.

2026-06-09 21:22:12 ET Olema Pharmaceuticals, Inc. (OLMA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 3:20 PM EDT... Read the full article on Seeking Alpha For further details see: Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th...

2026-06-01 09:24:44 ET Denver, Colorado ( www.247marketnews.com ) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive no...

Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCIS...

2026-05-22 08:15:09 ET H.C. Wainwright analyst issues BUY recommendation for OLMA on May 22, 2026 10:54AM ET. The previous analyst recommendation was Buy. OLMA was trading at $14.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monoth...

2026-05-15 09:55:45 ET Olema Pharmaceuticals ( OLMA ) published decent trial results in October last year, but the stock dropped ~30%. Then Roche published its own trial data in November, and the stock more than tripled—only to go down again in March when Roche publis...

2026-05-12 07:15:09 ET More on Olema Pharmaceuticals Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript...

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities ...

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cance...

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer ...